US Stock Insider Trading | Nuvalent disclosed 5 insider transactions on February 2

K-LinePoet · 2026-02-04T01:46:35+00:00

Nuvalent disclosed multiple insider transactions by executive Noci Darlene on January 29, 2026, including the purchase of 5,500 shares and several sales. Additionally, the company focuses on providing precision targeted therapies for cancer patients to address the limitations of existing treatments.

K-LinePoet

2026-02-04 01:46:35

Abstract generation in progress

On February 2, 2026, Nuvalent (NUVL) disclosed five insider transactions. Executive Noci Darlene purchased 5,500 shares on January 29, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Noci Darlene	January 29, 2026	Sell	1,819	102.67	$186,800
February 2, 2026	Executive	Noci Darlene	January 29, 2026	Sell	63	103.39	$6,513.57
February 2, 2026	Executive	Noci Darlene	January 29, 2026	Sell	189	100.95	$19,100
February 2, 2026	Executive	Noci Darlene	January 29, 2026	Buy	5,500	27.85	$153,200
February 2, 2026	Executive	Noci Darlene	January 29, 2026	Sell	3,429	101.80	$349,100
January 23, 2026	Executive	Miller Deborah Ann	January 22, 2026	Buy	15,000	27.85	$417,800
January 23, 2026	Executive	Miller Deborah Ann	January 22, 2026	Sell	14,300	110.16	$1,575,300
January 23, 2026	Executive	Miller Deborah Ann	January 21, 2026	Sell	700	109.84	$76,900
January 7, 2026	Director	Porter James Richard	January 5, 2026	Sell	4,727	96.85	$457,800
January 7, 2026	Director	Porter James Richard	January 6, 2026	Sell	3,963	96.75	$383,400

【Company Information】

Nuvalent, Inc. was incorporated on January 25, 2017, under the laws of Delaware. The company is a clinical-stage biopharmaceutical company focused on creating precision targeted therapies for cancer patients. The company leverages its team’s deep expertise in chemistry and structure-based drug design to develop innovative small molecules aimed at overcoming limitations of existing therapies targeting clinically validated kinase targets. Current kinase inhibitors face potential limitations such as (i) kinase resistance, where mutations in kinase targets render existing therapies ineffective, (ii) kinase selectivity, where current therapies may inhibit structurally similar kinases causing off-target adverse events, and (iii) limited blood-brain barrier penetration, affecting the ability to treat diseases that have spread or metastasized to the brain.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.